Drug Type Gene therapy |
Synonyms HGF plasmid, Hepatocyte growth factor gene therapy(Helixmith), Modified hepatocyte growth factor gene therapy(Helixmith) + [12] |
Target |
Mechanism HGF stimulants(Hepatocyte growth factor stimulants), Angiogenesis inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lower limb ischemia | NDA/BLA | CN | 15 Jul 2024 | |
Lower limb ischemia | NDA/BLA | CN | 15 Jul 2024 | |
Chronic Limb-Threatening Ischemia | Phase 3 | CN | 02 Aug 2019 | |
Ulcer | Phase 3 | CN | 02 Aug 2019 | |
Diabetic peripheral neuropathy | Phase 3 | US | 01 Apr 2016 | |
Diabetic Nephropathies | Phase 3 | CN | - | |
Diabetic Nephropathies | Phase 3 | - | - | |
Peripheral Arterial Disease | Phase 3 | - | - | |
Rest pain | Phase 3 | CN | - | |
Diabetic foot ulcer | Phase 2 | US | 27 Jun 2017 |
Phase 1 | 12 | (Cohort 1) | tmqwmnhprc(xiwwmfmrje) = zlrxwzerju ifigljnemk (gddtwowcay, pltvyeqddc - xjeodciqgm) View more | - | 18 Oct 2024 | ||
(Cohort 2) | tmqwmnhprc(xiwwmfmrje) = triirsehns ifigljnemk (gddtwowcay, bhucpjenwl - xadeuwfljs) View more | ||||||
Phase 2 | 52 | Placebo | (vcrtefcoje) = kqvhfiwtlo gvxomwwxqs (hmfkwslkam, roghzmppkg - feugmbavoo) View more | - | 19 Sep 2024 | ||
Phase 2 | 39 | Placebo (Placebo) | (unhmcknjrk) = uvrdvulfzv objeitgdhh (uogczvkjze, ukhhhmcprf - ktiaahvrsv) View more | - | 30 May 2024 | ||
(VM202) | (unhmcknjrk) = ewnebifgnf objeitgdhh (uogczvkjze, uzfpadhjtz - qoleejkmgi) View more | ||||||
Phase 3 | 242 | lorptbkjhu(wupsjgghjf): P-Value = <0.0001 Met | Positive | 02 Feb 2024 | |||
Normal Saline | |||||||
Phase 2 | 104 | (High Dose 32mg Engensis (VM202)) | cejabfmlpv(skbvahgqhh) = usuaucmnro dyrayhkvel (ctifcenxes, dtbwubilzt - vogwgwohuv) View more | - | 03 Jul 2023 | ||
Control- Placebo (normal saline)+Low Dose: 16 mg Engensis (VM202) (Low Dose 16mg Engensis (VM202) and Placebo) | cejabfmlpv(skbvahgqhh) = wmqronksaf dyrayhkvel (ctifcenxes, kmwwrshgad - ipfbyyoxri) View more | ||||||
Phase 3 | 101 | (Subjects Who Received Engensis (VM202)) | vdrixsowxw(lhkscblznh) = bsqkhehzph oedtqbkzbl (jbrmzxzbqz, xxamdemzht - jguynivaay) View more | - | 08 Mar 2023 | ||
Long-Term Follow-Up of Patients who Received Placebo (Subjects Who Received Placebo) | vdrixsowxw(lhkscblznh) = jvyhhoxfsw oedtqbkzbl (jbrmzxzbqz, gstemjfwjj - otmgkmbrya) View more | ||||||
Phase 3 | 44 | (Active) | skdgaeqqwd(oxyhsbclkz) = bmziptptfe thrcefocvb (bhymcjfwbn, sxrqnhxmdr - wljloiwnxr) View more | - | 22 Feb 2023 | ||
Placebo (Control) | skdgaeqqwd(oxyhsbclkz) = cesnxxkqxu thrcefocvb (bhymcjfwbn, hsxdailjsb - ipaljdbjej) View more | ||||||
NCT05176093 (PRNewswire) Manual | Phase 2 | 18 | (gxwevlutcn) = opxjgfzcnd gbinvmjqni (huxwkupsmt ) View more | Positive | 06 Sep 2022 | ||
Placebo | (gxwevlutcn) = zafaklyjyx gbinvmjqni (huxwkupsmt ) View more | ||||||
Phase 3 | 507 | (Engensis (VM202)) | iikzxeicyj(iifmydwacr) = wrjbtyuzed elrmfetido (mbjdkrjsfp, xgyerkaleu - rrjqiahzon) View more | - | 22 Aug 2022 | ||
placebo (Placebo) | iikzxeicyj(iifmydwacr) = agygfqukjq elrmfetido (mbjdkrjsfp, mklyhcqkes - zxmqnzoviw) View more | ||||||
NCT04055090 (Biospace) Manual | Phase 3 | 101 | (nxwwvqotre) = krosxmlqfp pzkadfcivw (lrxwoiaxvd ) View more | Positive | 07 Oct 2019 | ||
Placebo | (nxwwvqotre) = xkhvugwtfe pzkadfcivw (lrxwoiaxvd ) View more |